FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity: A Three Dimentional Echocardiography Study. PMID 37858847 · Curr Probl Cardiol · 2024-Jan The study is a randomized, controlled trial in oncology patients with a drug intervention (atorvastatin), but it lacks a primary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). The primary endpoint is echocardiographic measure of cardiac function (LVEF change and CTRCD incidence), which is a safety/toxicity endpoint, not a cancer efficacy endpoint. Phase is not explicitly reported as Phase III or equivalent definitive phase. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Improving the efficacy and safety of concurrent chemoradiotherapy by neoadjuvant chemotherapy: a randomized controlled study of locally advanced cervical cancer with a large tumor. PMID 37857565 · J Gynecol Oncol · 2024-Jan The record describes a randomized controlled trial in oncology with a drug intervention and reports primary time-to-event efficacy (OS). However, the publication types and abstract do not explicitly state the trial phase as Phase III/IIIb or Phase II/III. The deterministic review flagged phase evidence as unclear. Without explicit phase confirmation, the record cannot be confirmed as meeting all required eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-Term Physical Activity and Body Composition After Exercise and Educational Programs for Breast Cancer: A Randomized Controlled Trial From the Setouchi Breast Project-10. PMID 37852895 · Clin Breast Cancer · 2024-Jan The study is a randomized controlled trial in oncology with original results, but it is not a Phase III/IIIb or Phase II/III trial, does not involve a drug intervention, and its primary endpoint is not a time-to-event efficacy measure. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial. PMID 37852850 · Eur Urol · 2024-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma. PMID 37845285 · Leukemia · 2024-Jan The record describes a long-term follow-up report of a randomized trial in human oncology with a drug-containing intervention (ABVD chemotherapy) and a primary time-to-event efficacy endpoint (PFS). The trial design (HD16) is definitive and practice-changing for early-stage Hodgkin lymphoma, fitting the criteria for a Phase III/definitive trial despite the abstract not explicitly stating the phase number. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | confirmed 1 Figure · 1 Panel · risk visible |
| Immune profiling of pancreatic cancer for radiotherapy with immunotherapy and targeted therapy: Biomarker analysis of a randomized phase 2 trial. PMID 37820884 · Radiother Oncol · 2024-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria. PMID 37804344 · Ann Hematol · 2024-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Establishment and validation of a prognostic nomogram for patients with colorectal neuroendocrine carcinoma. PMID 37778975 · Asian J Surg · 2024-Jan The record is a retrospective prognostic nomogram study using registry (SEER) and hospital data, not a randomized controlled trial of a drug intervention. It lacks explicit Phase III evidence and a drug-containing intervention arm, which are required for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Impact of Hippocampal-Sparing Whole-Brain Radiotherapy on Survival and Cognitive Function in Patients with Brain Metastases. PMID 37773653 · Altern Ther Health Med · 2024-Jan The study is a randomized oncology trial with primary results including OS and PFS, but it evaluates a radiotherapy technique (hippocampal-sparing WBRT) versus conventional WBRT. It does not contain a drug-containing intervention as defined by the criteria (systemic therapy). The trial phase is not explicitly stated in the provided metadata, but even if it were Phase III, the absence of a drug intervention makes it ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Extended nodal radiotherapy for prostate cancer relapse guided with [11C]-choline PET/CT: ten-year results in patients enrolled in a prospective trial. PMID 37747578 · Eur J Nucl Med Mol Imaging · 2024-Jan The study is a prospective single-arm trial of radiotherapy for prostate cancer relapse. It is oncological, human, reports time-to-event endpoints (including OS), and is an original result. However, it is not randomized, does not involve a drug intervention (only radiotherapy and ADT as standard of care, not a drug-focused trial), and is not a Phase III or definitive randomized trial. It fails the core eligibility criteria of being a randomized Phase III/IIIb or Phase II/III trial with a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study. PMID 37737952 · BioDrugs · 2024-Jan The study is a randomized Phase III trial with a drug intervention and a primary efficacy endpoint. However, it is not an oncology study (it investigates spondyloarthritis) and does not have a time-to-event primary or key secondary endpoint. Therefore, it fails the fundamental oncology and time-to-event criteria for the cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The safety and effectiveness of laparoscopic off-clamp tumor evacuation versus traditional nephron-sparing surgery for large (>4 cm) sporadic renal angiomyolipomas. PMID 37640651 · Asian J Surg · 2024-Jan 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Lobectomy, segmentectomy, or wedge resection for peripheral clinical T1aN0 non-small cell lung cancer: A post hoc analysis of CALGB 140503 (Alliance). PMID 37473998 · J Thorac Cardiovasc Surg · 2024-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Immunotherapy in the First-Line Treatment of Advanced Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis. PMID 37227161 · Laryngoscope · 2024-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Randomized trial promoting cancer genetic risk assessment when genetic counseling cost removed: 1-year follow-up. PMID 38490263 · JNCI Cancer Spectr · 2024-Feb-29 The study is a randomized controlled trial in oncology patients, but it lacks a drug-containing intervention and a time-to-event clinical efficacy endpoint. The intervention is counseling and cost removal, and the time-to-event measure (Kaplan-Meier for CGRA uptake) is not a primary efficacy endpoint like OS/PFS. Phase information is also not explicitly provided. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer. PMID 38416430 · N Engl J Med · 2024-Feb-29 Excluded due to non-drug intervention (surgical comparison) and lack of a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR). The primary outcome is 3-year pelvic recurrence incidence, a binary event rate, not a time-to-event analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparative efficacy and therapeutic positioning of biologics in hidradenitis suppurativa: A systematic review with network meta-analysis of randomised trials. PMID 38595016 · Indian J Dermatol Venereol Leprol · 2024-Feb-28 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Camrelizumab in combination with chemotherapy versus concurrent chemoradiotherapy for the conversion of locally advanced unresectable oesophageal squamous carcinoma: protocol for a two-arm, open-label phase II trial. PMID 38418234 · BMJ Open · 2024-Feb-28 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial. PMID 38413930 · BMC Med · 2024-Feb-27 The record is excluded because the trial phase is not established as Phase III/IIIb or Phase II/III, which is a required criterion for eligibility. While the study is oncology-related (hematologic malignancies), randomized, and reports time-to-event outcomes, it does not meet the definitive-phase requirement. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML. PMID 38197938 · Blood Adv · 2024-Feb-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Outcomes of a Dietary Intervention to Reduce Bladder Cancer Recurrence and Progression in Survivors of Non-Muscle-Invasive Bladder Cancer. PMID 38408431 · J Natl Compr Canc Netw · 2024-Feb-26 Study is a randomized trial in oncology (bladder cancer) with original results, but it is not a Phase III/IIIb or Phase II/III trial (phase not specified but methods imply a pilot/intervention-focused study), does not involve a drug-containing intervention (dietary cruciferous vegetables vs general fruit/vegetable), and lacks a time-to-event efficacy endpoint (primary outcome is urinary ITC level; no OS/PFS/DFS/KM/HR reported). |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy of adding levofloxacin to gemcitabine and nanoparticle-albumin-binding paclitaxel combination therapy in patients with advanced pancreatic cancer: study protocol for a multicenter, randomized phase 2 trial (T-CORE2201). PMID 38402399 · BMC Cancer · 2024-Feb-24 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial. PMID 38402173 · BMC Cancer · 2024-Feb-24 The record describes a protocol for a randomized trial in oncology with a drug intervention and a time-to-event primary endpoint (overall survival), but it is explicitly a protocol without results. The phase (Phase III/IIIb or Phase II/III) is not established in the provided metadata, and the report is not an original result report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Effect of venetoclax plus chemotherapy on treatment-naive acute myeloid leukemia patients with moderate to poor cytogenetic profiles and the combination's influence on the expression of proteins of the anti-apoptoic family]. PMID 38418191 · Zhonghua Zhong Liu Za Zhi · 2024-Feb-23 The study is an oncology randomized trial with a drug intervention and reports time-to-event endpoints. However, it is not confirmed as a Phase III/IIIb or Phase II/III trial, which is a required criterion. The abstract describes it as an 'open-label observational assessment,' and MeSH terms include 'Retrospective Studies,' suggesting it may not be a definitive randomized trial. Therefore, it does not meet all required eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Protocol for the ONLOOP trial: pragmatic randomized trial evaluating a province-wide system of personalized reminders for evidence-based surveillance tests in adult survivors of childhood cancer in Ontario. PMID 38395903 · Implement Sci · 2024-Feb-23 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| #4Corners4Health Social Media Cancer Prevention Campaign for Emerging Adults: Protocol for a Randomized Stepped-Wedge Trial. PMID 38386396 · JMIR Res Protoc · 2024-Feb-22 Protocol for a randomized stepped-wedge trial evaluating a social media campaign for cancer prevention behaviors. While it is oncology-related, human, and randomized, it lacks a drug-containing intervention (focus is on health behaviors like HPV vaccination, diet, physical activity), does not report a Phase III/IIIb or Phase II/III trial, and has no time-to-event efficacy endpoint (OS, PFS, etc.) or Kaplan-Meier/HR results. It is a protocol without results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Efficacy of Bepotastine Besilate Compared With Hydroxyzine Pamoate for Preventing Infusion Reactions to the First Dose of Rituximab in Patients With Non-Hodgkin Lymphoma: Protocol for a Phase II, Double-Blind, Multicenter Randomized Trial. PMID 38386393 · JMIR Res Protoc · 2024-Feb-22 The record is a protocol for an ongoing Phase II randomized trial. It is oncology-related, human, randomized, and involves drug interventions. However, it is not a Phase III trial, does not report final efficacy results, and its primary endpoint (incidence of severe infusion reactions) is not a time-to-event efficacy endpoint like OS, PFS, or DFS. The deterministic review correctly identified the lack of time-to-event signal. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Parecoxib sodium down-regulates CXCL8-CXCR1/2 to improve inflammatory microenvironment and promote patient recovery following laparoscopic radical resection of rectal cancer]. PMID 38501422 · Nan Fang Yi Ke Da Xue Xue Bao · 2024-Feb-20 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Fasting-mimicking diet causes hepatic and blood markers changes indicating reduced biological age and disease risk. PMID 38378685 · Nat Commun · 2024-Feb-20 The study is a randomized clinical trial in humans with oncology-related context, but it is not a Phase III/IIIb or Phase II/III trial. The intervention is a fasting-mimicking diet, not a drug-containing intervention. The endpoints are cardiometabolic risk factors and biomarkers of biological age, not time-to-event efficacy outcomes like OS, PFS, or DFS. The report is a secondary analysis of trial data. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Recurrences of advanced sessile and lateral spreading colorectal adenoma after endoscopic mucosal resection (EMR) thermal ablation versus no adjuvant therapy (RESPECT): a protocol of an international randomized controlled trial. PMID 38368409 · Trials · 2024-Feb-17 The record describes a protocol for an international randomized controlled trial evaluating endoscopic mucosal resection with thermal ablation for colorectal adenoma. While it is oncology, human, and randomized, it is ineligible because it is a protocol without results, the intervention is a non-drug procedural technique, and the primary endpoint is not a time-to-event efficacy measure. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness of the ONCORAL multidisciplinary programme for the management of outpatients taking oral anticancer agents at risk of drug-related event: protocol for a pragmatic randomised controlled study. PMID 38367968 · BMJ Open · 2024-Feb-17 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Application of the patient-reported outcome-based postoperative symptom management model in lung cancer: a multicenter randomized controlled trial protocol. PMID 38365704 · Trials · 2024-Feb-17 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. PMID 38246194 · Lancet · 2024-Feb-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden. PMID 37801329 · Clin Cancer Res · 2024-Feb-16 The record is a subgroup/biomarker analysis from a known Phase III trial (CASPIAN), but the abstract does not explicitly state the phase, and the analysis is exploratory. Therefore, it is excluded as it is not a primary result report and the phase is not explicitly confirmed in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Development and validation of a nomogram for predicting suicide risk and prognostic factors in bladder cancer patients following diagnosis: A population-based retrospective study. PMID 38000463 · J Affect Disord · 2024-Feb-15 This is a retrospective observational study using SEER data to develop a suicide risk prediction nomogram for bladder cancer patients. It is not a randomized controlled trial of a drug intervention, and the primary endpoint is suicide risk (not a standard oncology time-to-event efficacy endpoint like OS, PFS, etc.). Therefore, it does not meet the inclusion criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Outpatient follow-up of tumour diseases through video-based value-oriented behavioural activation (ViVA): study protocol for a randomised controlled trial. PMID 38355525 · Trials · 2024-Feb-14 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Integrating artificial intelligence into lung cancer screening: a randomised controlled trial protocol. PMID 38355174 · BMJ Open · 2024-Feb-13 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| A Digital Intervention to Improve Skin Self-Examination Among Survivors of Melanoma: Protocol for a Type-1 Hybrid Effectiveness-Implementation Randomized Trial. PMID 38345836 · JMIR Res Protoc · 2024-Feb-12 This is a protocol for a randomized trial evaluating a digital intervention (mySmartSkin) to improve skin self-examination in melanoma survivors. It does not involve a drug intervention, does not specify a Phase III/IIIb or Phase II/III trial, and lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR reporting. It is a protocol without results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer. PMID 38127780 · J Clin Oncol · 2024-Feb-10 The record is an FDA Approval Summary summarizing the PROpel trial. While the abstract describes a randomized trial with drug intervention and a primary time-to-event endpoint, the report is not the original formal publication of the trial results. Additionally, the trial phase is not explicitly stated as Phase III or Phase II/III in the provided text or metadata, making the phase criterion ambiguous. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. PMID 37963304 · J Clin Oncol · 2024-Feb-10 Eligible: Confirmed Phase III randomized trial (PROfound) evaluating Olaparib in human oncology with primary/time-to-event efficacy endpoints (PFS, OS). The deterministic review flagged randomized evidence as unclear, but the full record context (title, abstract, publication type) confirms a Phase III randomized trial with a drug intervention and Kaplan-Meier/HR analysis. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial. PMID 37883738 · J Clin Oncol · 2024-Feb-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Effect of a Community Health Worker-Led Intervention Among Low-Income and Minoritized Patients With Cancer: A Randomized Clinical Trial. PMID 37625110 · J Clin Oncol · 2024-Feb-10 The trial is oncology, human, randomized, and reports original results with overall survival as a secondary endpoint. However, it is ineligible because it lacks a drug-containing intervention (the intervention is a non-drug community health worker-led program) and the primary/key secondary efficacy endpoint for inclusion is time-to-event (e.g., OS, PFS), but the primary outcome is quality of life. The drug_intervention criterion is explicitly not met. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| High frequency electrocoagulation resection effect analysis and prognosis observation in the treatment of patients with gastric polyps under painless gastroscopy. PMID 38335390 · Medicine (Baltimore) · 2024-Feb-09 The study investigates gastric polyps (benign lesions) with a procedural intervention (electrocoagulation resection) and reports symptom scores, healing, and recurrence rates, not oncology or time-to-event efficacy endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Survivorship Care for Women Living With Ovarian Cancer: Protocol for a Randomized Controlled Trial. PMID 38335019 · JMIR Res Protoc · 2024-Feb-09 This is a protocol for a randomized controlled trial in ovarian cancer survivors testing a survivorship care platform. The primary endpoint is quality of life at 12 weeks, not a time-to-event outcome (OS, PFS, DFS, etc.). The study includes patients on maintenance therapy, but the intervention is a care platform, not a drug. It is a protocol paper with no results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Feasibility and efficacy of pre-management of superior laryngeal artery in endoscopic surgery for hypopharyngeal cancer]. PMID 38310372 · Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi · 2024-Feb-07 Study is an oncology, human, randomized trial with a disease-free survival endpoint and original results, but it is not a Phase III/IIIb or Phase II/III trial (phase is not specified or confirmed as definitive) and does not involve a drug-containing intervention (it is a surgical technique comparison). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome. PMID 38321023 · Nat Commun · 2024-Feb-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of Colonoscopy Screening vs Sigmoidoscopy Screening in Colorectal Cancer. PMID 38421651 · JAMA Netw Open · 2024-Feb-05 The study is a randomized, oncology, human trial, but it does not meet the key eligibility criteria: it lacks a drug-containing intervention and does not report a time-to-event efficacy endpoint. The primary outcomes are incidence and mortality rates, not survival or progression curves. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Smoking Status and Survival in Patients With Early-Stage Primary Cutaneous Melanoma. PMID 38319662 · JAMA Netw Open · 2024-Feb-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer? PMID 38318930 · Cancer Biol Med · 2024-Feb-05 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Low-dose acetylsalicylic acid reduces local inflammation and tissue perfusion in dense breast tissue in postmenopausal women. PMID 38317255 · Breast Cancer Res · 2024-Feb-05 The study is a randomized trial with a drug intervention in a breast cancer risk population, but it is not a Phase III treatment trial for established malignancy and lacks a time-to-event clinical efficacy endpoint (e.g., OS, PFS, DFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |